17-DMAG Hydrochloride Salt Alvespimycin (CAS: 467214-21-7) is a small molecule inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone involved in the regulation of protein folding and stability. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors and hematological malignancies.
Chemical name: 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin hydrochloride
Molecular formula: C31H43ClN4O8
Formula weight: 662.16 g/mol
CAS No: 467214-21-7
Top ten keywords from Google:
Synonyms:
Health benefits of this product: 17-DMAG Hydrochloride Salt Alvespimycin has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of solid tumors and hematological malignancies. Its primary mode of action is through the inhibition of Hsp90, leading to destabilization of client proteins involved in cancer cell survival and proliferation.
Potential effects: 17-DMAG Hydrochloride Salt Alvespimycin has demonstrated efficacy in several preclinical studies in inhibiting the activity of Hsp90, leading to reduced cancer cell proliferation and increased apoptosis. It also has potential benefits for inducing cell cycle arrest, reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and inhibiting signal transduction pathways that regulate cell survival and proliferation. 17-DMAG Hydrochloride Salt Alvespimycin works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: 17-DMAG Hydrochloride Salt Alvespimycin works by inhibiting the activity of Hsp90, a molecular chaperone involved in the regulation of protein folding and stability. Hsp90 plays an essential role in stabilizing client proteins involved in cancer cell survival and proliferation. By inhibiting Hsp90 activity, 17-DMAG Hydrochloride Salt Alvespimycin can destabilize client proteins, leading to reduced tumor growth and increased apoptosis.
Safety: 17-DMAG Hydrochloride Salt Alvespimycin has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Rare but potential side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking 17-DMAG Hydrochloride Salt Alvespimycin, as it may affect these conditions. Pregnant or breastfeeding women should avoid using 17-DMAG Hydrochloride Salt Alvespimycin, as its safety in these populations has not been established.
Side effects: Common side effects of 17-DMAG Hydrochloride Salt Alvespimycin may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of 17-DMAG Hydrochloride Salt Alvespimycin may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 10 to 150 mg/kg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: 17-DMAG Hydrochloride Salt Alvespimycin (CAS: 467214-21-7) is a small molecule inhibitor of Hsp90, a molecular chaperone involved in the regulation of protein folding and stability. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors and hematological malignancies. Although it has been generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and cancer types.
